Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Itacitinib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 20 May 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 30 Jul 2018 to 30 Nov 2019.
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 06 Mar 2018 Planned initiation date changed from 30 Sep 2017 to 30 Jul 2018.